{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:13Z","timestamp":1786119613623,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,2]]},"DOI":"10.1097\/qad.0b013e328341685b","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T05:01:48Z","timestamp":1290229308000},"page":"65-71","source":"Crossref","is-referenced-by-count":66,"title":["A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine"],"prefix":"10.1097","volume":"25","author":[{"given":"Laura","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Hadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundhiya","family":"Mandalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackie","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archinternmed.2009.432","article-title":"Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008","volume":"170","author":"Elzi","year":"2010","journal-title":"Arch Intern Med"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/jac\/dkp334","article-title":"Efavirenz: a decade of clinical experience in the treatment of HIV","volume":"64","author":"Maggiolo","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1468-1293.2006.00419.x","article-title":"Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study","volume":"7","author":"Rihs","year":"2006","journal-title":"HIV Med"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1310\/hct1006-343","article-title":"Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)","volume":"10","author":"Clifford","year":"2009","journal-title":"HIV Clin Trials"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1097\/QAD.0b013e3283316a5e","article-title":"Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials","volume":"23","author":"Katlama","year":"2009","journal-title":"AIDS"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3851\/IMP1562","article-title":"Pharmacokinetics of once-daily etravirine without and with once-daily darunavir\/ritonavir in antiretroviral-naive HIV type-1-infected adults","volume":"15","author":"DeJesus","year":"2010","journal-title":"Antivir Ther"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/QAI.0b013e3181b061d0","article-title":"Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers","volume":"52","author":"Boffito","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral- naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J Infect Dis"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na\u00efve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV- infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1258\/ijsa.2009.008487","article-title":"Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients","volume":"21","author":"Campo","year":"2010","journal-title":"Int J STD AIDS"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/605674","article-title":"Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial","volume":"49","author":"De Castro","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/apc.2006.20.542","article-title":"Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles","volume":"20","author":"Ward","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/518973","article-title":"Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study","volume":"45","author":"Parienti","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201101020-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:42:36Z","timestamp":1786041756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201101020-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328341685b","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,2]]}}}